Skip to Content

Bamlanivimab + Etesevimab Reduces SARS-CoV-2 Viral Load

FRIDAY, Jan. 22, 2021 -- Treatment with bamlanivimab and etesevimab, but not monotherapy with bamlanivimab, is associated with a reduction in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in patients with mild-to-moderate COVID-19, according to a study published online Jan. 21 in the Journal of the American Medical Association.

Robert L. Gottlieb, M.D., Ph.D., from the Baylor University Medical Center and Baylor Scott and White Research Institute in Dallas, and colleagues randomly assigned 577 patients who tested positive for SARS-CoV-2 infection and had one or more mild-to-moderate symptoms to receive either a single infusion of bamlanivimab monotherapy (700 mg, 2,800 mg, or 7,000 mg [101, 107, and 101 patients, respectively]), combination treatment (2,800 mg bamlanivimab and 2,800 mg etesevimab [112 patients]), or placebo (156 patients).

In the phase 2 portion of this phase 2/3 randomized trial, the researchers found that the change in log viral load from baseline at day 11 was −3.72, −4.08, −3.49, −4.37, and −3.80 for 700, 2,800, and 7,000 mg bamlanivimab, combination treatment, and placebo, respectively. The differences in the change in log viral load at day 11 were 0.09 (95 percent confidence interval [CI], −0.35 to 0.52; P = 0.69), −0.27 (95 percent CI, −0.71 to 0.16; P = 0.21), 0.31 (95 percent CI, −0.13 to 0.76; P = 0.16), and −0.57 (95 percent CI, −1.00 to −0.14; P = 0.01) for 700, 2,800, and 7,000 mg bamlanivimab and the combination treatment, respectively, versus placebo.

"Additional study is needed to understand whether the greater reduction of viral load shown by combination therapy would eventually translate to clinical benefit compared with monotherapy," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Eli Lilly and Company, which funded the trial.

Abstract/Full Text

Editor's Note

© 2021 HealthDay. All rights reserved.

Read this next

Frequency of Urgent Vitreoretinal Surgery Down During Pandemic

FRIDAY, March 5, 2021 -- The frequency of urgent or emergent vitreoretinal surgical procedures decreased during the COVID-19 pandemic, according to a study published online March...

Delayed Local Reactions to mRNA-1273 Vaccination Reported

FRIDAY, March 5, 2021 -- Twelve cases of delayed large local reactions to the mRNA-1273 vaccination against severe acute respiratory syndrome coronavirus 2 are described in a...

Ivermectin Does Not Speed Symptom Resolution in Mild COVID-19

FRIDAY, March 5, 2021 -- A five-day course of ivermectin does not improve the time to resolution of symptoms compared with placebo for adults with mild COVID-19, according to a...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.